QLi5 Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.2M
- Investors
-
8
QLi5 Therapeutics General Information
Description
Operator of a payload platform technology intended to scale to various indications. The company specializes in treating cancers and inflammatory and autoimmune disorders, enabling medical professionals to expand the treatment area for diseases.
Contact Information
Website
qli5tx.comCorporate Office
- Otto-Hahn-Straße 15
- 44227 Dortmund
- Germany
Corporate Office
- Otto-Hahn-Straße 15
- 44227 Dortmund
- Germany
QLi5 Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 27-Jan-2026 | $6.2M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series A) | 07-Sep-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 14-Dec-2021 | $5.65M | $5.65M | Completed | Generating Revenue | |
| 1. Joint Venture | 16-Jan-2020 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
QLi5 Therapeutics Patents
QLi5 Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4155296-A1 | Macrocyclic compounds as proteasome subunit beta type-5 inhibitors | Inactive | 24-Sep-2021 | ||
| WO-2023046939-A1 | Macrocyclic compounds as proteasome subunit beta type-5 inhibitors | Inactive | 24-Sep-2021 |
QLi5 Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Atinum Investment | Venture Capital | Minority | ||
| DAOL Investment | PE/Buyout | Minority | ||
| Khanu Management | Venture Capital | Minority | ||
| SV Investment | Venture Capital | Minority |
QLi5 Therapeutics FAQs
-
When was QLi5 Therapeutics founded?
QLi5 Therapeutics was founded in 2019.
-
Where is QLi5 Therapeutics headquartered?
QLi5 Therapeutics is headquartered in Dortmund, Germany.
-
What industry is QLi5 Therapeutics in?
QLi5 Therapeutics’s primary industry is Drug Discovery.
-
Is QLi5 Therapeutics a private or public company?
QLi5 Therapeutics is a Private company.
-
What is QLi5 Therapeutics’s current revenue?
The current revenue for QLi5 Therapeutics is .
-
How much funding has QLi5 Therapeutics raised over time?
QLi5 Therapeutics has raised $21.9M.
-
Who are QLi5 Therapeutics’s investors?
, Atinum Investment, DAOL Investment, Khanu Management, and SV Investment are 5 of 8 investors who have invested in QLi5 Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process